These findings were confirmed in clinical samples, which showed that expression of the active form of CHK2, i.e., phosphorylated CHK2 (p-CHK2), was significantly associated with nuclear BQ expression and poorer survival outcomes of ER + ve breast cancer patients. The gene discussed is CHEK2; the disease is breast cancer.